1. Introduction {#sec1-cancers-11-02031}
===============

Primary cutaneous melanomas (CMs) arising from the glabrous skin of the palms, soles, or nail apparatus are considered acral melanomas (AMs). It has been suggested that AMs are associated with a worse prognosis than other CMs, mainly because of advanced stage at presentation, which may be related to the relatively occult anatomic sites and inconspicuous appearance \[[@B1-cancers-11-02031],[@B2-cancers-11-02031],[@B3-cancers-11-02031],[@B4-cancers-11-02031],[@B5-cancers-11-02031],[@B6-cancers-11-02031]\]. Most AMs exhibit a lentiginous proliferation within the epidermis and are referred to as acral lentiginous melanoma (ALM), a rare subtype characterized by increased risk of metastasis and melanoma-specific death \[[@B1-cancers-11-02031],[@B2-cancers-11-02031],[@B3-cancers-11-02031]\]. ALM is the most common melanoma subtype in African American, Hispanic, and Asian individuals, accounting for 29% to 72% of CM cases in these populations \[[@B7-cancers-11-02031],[@B8-cancers-11-02031],[@B9-cancers-11-02031]\]. Genomic analyses of CM have yielded biological and therapeutic insights, but understanding of the molecular pathogenesis of AM remains limited \[[@B10-cancers-11-02031],[@B11-cancers-11-02031],[@B12-cancers-11-02031],[@B13-cancers-11-02031]\]. Whereas melanoma on sun-exposed sites harbors a large number of ultraviolet light--induced mutations commonly affecting genes regulating the MAPK pathway, it has been reported that AM is driven by a combination of amplifications of *TERT*, *CCND1*, *CDK4*, *MITF*, *PAK1*, *GAB2*, *YAP1*, and *MDM2* and mutations in *BRAF*, *NRAS*, *KIT*, and *PDGFRA* \[[@B10-cancers-11-02031],[@B11-cancers-11-02031],[@B12-cancers-11-02031],[@B13-cancers-11-02031]\].

Aberrant DNA methylation is a frequent epigenetic change in melanoma and has prognostic implications \[[@B14-cancers-11-02031]\]. Epigenetic changes are more frequent than genetic alterations in melanoma and are potentially reversible \[[@B15-cancers-11-02031],[@B16-cancers-11-02031],[@B17-cancers-11-02031],[@B18-cancers-11-02031]\]. Recent studies have revealed that promoter methylation of *PTEN* is an independent predictor of worse survival in melanoma \[[@B19-cancers-11-02031],[@B20-cancers-11-02031]\]. Methylation of *RARB*, *APC*, *CDH13*, *ESR1*, *CDKN2A*, *RASSF1*, *MGMT*, and *HOXD9* has been shown to be associated with poor survival in CM \[[@B21-cancers-11-02031],[@B22-cancers-11-02031],[@B23-cancers-11-02031],[@B24-cancers-11-02031],[@B25-cancers-11-02031],[@B26-cancers-11-02031]\]. AMs have relatively greater prevalence of DNA methylation than other types of CM and are significantly associated with *PTEN* and *CDH13* hypermethylation \[[@B21-cancers-11-02031]\]. Genome-wide mapping of 5-hydroxymethylcytosine revealed its loss in melanoma, and restoring active *TET2* or *IDH2* reactivated 5-hydroxymethylcytosine suppressed melanoma growth and increased tumor-free survival in animal models, suggesting the therapeutic potential of targeting epigenetic changes \[[@B27-cancers-11-02031],[@B28-cancers-11-02031]\].

Despite promising clinical responses to immune checkpoint blockade therapy and targeted therapy, the response of ALM to these agents remains unpredictable, underscoring a critical need to delineate additional prognostic and predictive biomarkers and/or novel therapeutic targets for this disease. To date, few studies have focused on identifying epigenetic prognostic biomarkers in AM \[[@B21-cancers-11-02031]\]. Here, we subclassified AMs into primary ALM (PALM), non-ALM-type melanomas involving acral skin (NALM, defined as AM that lacks lentiginous pattern of intraepidermal melanocytic growth; includes superficial spreading, lentigo maligna, and nodular types), and metastatic ALM (MALM), and interrogated the methylation profiles of AMs and primary non-acral CM (PCM). We aimed to compare the methylome of PALM and NALM as they are histologically distinct as well as primary AM and MALM, and determine the association of these methylome signatures with clinicopathologic features, overall survival (OS), and disease-specific survival (DSS).

2. Results {#sec2-cancers-11-02031}
==========

2.1. Clinicopathologic Features {#sec2dot1-cancers-11-02031}
-------------------------------

Most patients in our cohort were white men with intermediate or thick melanomas. The key clinicopathologic features are summarized in [Table 1](#cancers-11-02031-t001){ref-type="table"}.

2.2. Association of Melanoma Subtype with Clinicopathologic Parameters, Genetic Alterations, and Outcome {#sec2dot2-cancers-11-02031}
--------------------------------------------------------------------------------------------------------

There were no significant differences among melanoma subtypes in sex, age, race, American Joint Committee on Cancer (AJCC) stage, Clark level, Breslow thickness, mitotic rate, ulceration, regression, perineural invasion, microsatellitosis, or genetic alteration ([Table 1](#cancers-11-02031-t001){ref-type="table"}). Of all the histopathologic parameters examined, only perineural invasion was associated with worse survival (OS, *p* = 0.014; DSS, *p* = 0.019).

Although our sample size was too small to have statistical power for making a definite statement, patients with NALM (median: 5.0 years) had significantly worse DSS than patients with PALM (median not reached), MALM (median: 7.6 years), or PCM (median not reached) ([Figure 1](#cancers-11-02031-f001){ref-type="fig"}A,B) (*p* = 0.02 among all four groups \[PALM, MALM, NALM, and PCM\] and *p* = 0.024 among PALM, NALM, and PCM).

2.3. Performance of the Methylome Signature in Distinguishing Malignant from Benign Melanocytic Neoplasms {#sec2dot3-cancers-11-02031}
---------------------------------------------------------------------------------------------------------

The significant promoter-associated differentially methylated positions for all groups are summarized in [Supplementary Table S1](#app1-cancers-11-02031){ref-type="app"}. These positions constituted the methylome signature.

To ensure that the algorithm functioned adequately, we tested its performance in distinguishing malignant from benign acral melanocytic neoplasms. All cases of NALM and PCM were analyzed in parallel with AN. As expected, melanoma cases clustered tightly together and were clearly separated from AN cases ([Supplementary Figure S1A,B](#app1-cancers-11-02031){ref-type="app"}). NALM and PCM showed significant enrichment of the MAPK pathway, which seemed to be a more common epigenetic mechanism in these melanomas than in AN ([Supplementary Figure S2A; Supplementary Table S2](#app1-cancers-11-02031){ref-type="app"}).

2.4. Identification of a Primary Acral Lentiginous Melanoma (PALM)-Specific Methylome Signature {#sec2dot4-cancers-11-02031}
-----------------------------------------------------------------------------------------------

In order to identify a PALM-specific methylome signature, we compared the methylation profiles of PALM versus NALM and PALM versus MALM. The top 5000, 1000, 500, and 100 differentially methylated probes (DMPs) (the probes with the lowest associated *p* and *q* values) were selected ([Supplementary Table S2](#app1-cancers-11-02031){ref-type="app"}). Given the high correlations among all four sets of probes (*R*^2^ = 0.98), we present the heatmap based on the top 50 DMPs.

Unsupervised hierarchical clustering and multidimensional parametric analysis showed different methylation profiles and distinct clusters in the PALM and NALM groups ([Figure 2](#cancers-11-02031-f002){ref-type="fig"}A,B; [Supplementary Table S2](#app1-cancers-11-02031){ref-type="app"}). Four probes that were most differentially methylated between PALM and NALM co-localized to the promoter region of genes of interest: cg26732804 (*HHEX*), cg14397361 (*NELFB* \[formerly *COBRA1*\]), cg21298070 (*TEF*), and cg07088959 (*DIPK2A* \[formerly *C3orf58*\]). All four probes exhibited significant differences in methylation status between PALM and NALM with profound hypomethylation in PALM (specific identified cutoffs \<0.024, \<0.014, \<0.0434, and \<0.200, respectively; *p* = 0.0001, *p* = 0.047, *p* = 0.0014, and *p* = 0.0034, respectively) ([Supplementary Table S3](#app1-cancers-11-02031){ref-type="app"}). As expected, pathway network analysis revealed enrichment in 233 genes pertaining to the MAPK signaling pathway ([Supplementary Figure S2B; Supplementary Table S1](#app1-cancers-11-02031){ref-type="app"}).

When we compared PALM and MALM, we found that the four promoter-associated probes above-mentioned were among the most differentially methylated ([Figure 2](#cancers-11-02031-f002){ref-type="fig"}C,D; [Supplementary Table S1](#app1-cancers-11-02031){ref-type="app"}). Three of the four probes exhibited significant differences in methylation status between PALM and MALM with profound hypomethylation (using the above-mentioned cutoffs) in PALM (*HHEX*, *p* = 0.04; *DIPK2A*, *p* = 0.02; *NELFB*, *p* = 0.002); there was no significant methylation difference in *TEF* (*p* = 0.11) ([Supplementary Table S3](#app1-cancers-11-02031){ref-type="app"}). Notably, cg26732804 (*HHEX*) showed a greater range of hypomethylation than the other three probes, with hypomethylation in 14 (73%) of 19 PALM cases versus three (30%) of 10 MALM cases. Pathway network analysis revealed enrichment in 273 genes pertaining to the HPV signaling pathway ([Supplementary Figure S3A; Supplementary Table S1](#app1-cancers-11-02031){ref-type="app"}). Notably, when we compared NALM and MALM, the cases in each subgroup showed discrete clustering with the exception of MALM5 that clustered with the NALM group ([Figure 2](#cancers-11-02031-f002){ref-type="fig"}G,H).

2.5. Association of PALM-Specific Methylome Signature with Clinicopathologic Parameters and Outcome {#sec2dot5-cancers-11-02031}
---------------------------------------------------------------------------------------------------

Univariate Cox proportional hazards regression models showed that hypermethylation of *HHEX* and *NELFB* significantly correlated with poor OS (*HHEX*: hazard ratio \[HR\], 4.60; 95% CI, 1.63 to 13.00; *p* = 0.004; *NELFB*: HR, 4.75; 95% CI, 1.61 to 13.99; *p* = 0.005) and poor DSS (*HHEX*: HR, 6.13; 95% CI, 1.83 to 20.49; *p* = 0.003; *NELFB*: HR, 7.17; 95% CI, 1.92 to 26.76; *p* = 0.003). Kaplan--Meier survival analysis also demonstrated that hypermethylation of *HHEX* and *NELFB* significantly correlated with poor OS ([Supplementary Figure S4A,B](#app1-cancers-11-02031){ref-type="app"}) and poor DSS ([Figure 1](#cancers-11-02031-f001){ref-type="fig"}C,D). Hypermethylation of cg26732804 (*HHEX*) and cg14397361 (*NELFB*) was significantly associated with the presence of lymph node metastasis (odds ratio \[OR\], 7.50; 95% CI, 1.61 to 34.95; *p* = 0.01 and OR, 5.50; 95% CI, 1.16 to 26.14; *p* = 0.032, respectively). These findings corroborated the prognostic impact of hypermethylation of these loci on survival ([Table 2](#cancers-11-02031-t002){ref-type="table"}). Another probe identified among the top 50 DMPs was cg02753722 (*CDH13)*. Using the identified cutoff (\<0.226), hypermethylation of cg02753722 (*CDH13*) was associated with worse OS and DSS among patients with AM (PALM + NALM) (*p* = 0.015 and *p* = 0.0009, respectively). cg21298070 (*TEF*) hypermethylation was associated with a higher mitotic rate (\>10) (OR, 14.44; 95% CI, 1.56 to 133.6; *p* = 0.019).

Aberrant methylation was significantly associated with aggressive clinicopathologic parameters including the presence of lymph node metastasis, higher Breslow thickness, increased mitoses, ulceration, and perineural invasion ([Table 2](#cancers-11-02031-t002){ref-type="table"}). Kaplan--Meier survival analysis demonstrated significant correlations between the hypomethylation of *CDH13* and worse OS and DSS ([Supplementary Figure S4C,D](#app1-cancers-11-02031){ref-type="app"}) and between the hypermethylation of *DIPK2A* ([Figure 1](#cancers-11-02031-f001){ref-type="fig"}E) and *TEF* ([Figure 1](#cancers-11-02031-f001){ref-type="fig"}F) and worse DSS ([Table 2](#cancers-11-02031-t002){ref-type="table"}).

2.6. Identification of a Specific Methylome Signature Associated with Metastasis from Acral Melanomas (AMs) {#sec2dot6-cancers-11-02031}
-----------------------------------------------------------------------------------------------------------

Primary AMs have a significantly better survival than MALM \[[@B1-cancers-11-02031],[@B12-cancers-11-02031]\]. It is important to find prognostic biomarkers that may serve to risk-stratify patients with AM at an early stage of the disease. Comparison of both groups of primary AM (PALM and NALM) to their metastatic counterparts (MALM) showed distinct clusters corresponding to primary and metastatic tumors ([Figure 2](#cancers-11-02031-f002){ref-type="fig"}E,F; [Supplementary Table S1](#app1-cancers-11-02031){ref-type="app"}). Pathway network analysis revealed enrichment in 233 genes pertaining to the MAPK signaling pathway ([Supplementary Figure S3B; Supplementary Table S2](#app1-cancers-11-02031){ref-type="app"}). We identified 25 shared probes within the top 50 DMPs in the PALM versus MALM and PALM + NALM versus MALM analyses ([Supplementary Figure S5](#app1-cancers-11-02031){ref-type="app"}). Within this 25-probe set, two probes, cg11694510 and cg09923443, localized to the promoter regions of *IFITM1* and *SIK3,* respectively. These probes exhibited significantly different levels of methylation between primary and metastatic AM, with profound hypomethylation in the primary tumors (*SIK3*, *p* \< 0.0001; *IFITM1*, *p* \< 0.0001), highlighting their pivotal role in the initiation of metastasis. Additionally, there was a statistically significant difference (*p* = 0.03) in the methylation status of the *MYC* promoter (probe cg24666276) between primary and metastatic cases with a tendency to hypomethylation in the metastatic cases, suggesting overexpression of MYC and corroborating its role in metastasis. Probe cg11694510 (*IFITM1*) did not show evidence of hypomethylation in any of the MALM cases, but was profoundly hypomethylated in six of 28 (21%) primary (PALM + NALM) cases. Similarly, cg09923443 (*SIK3*) was hypomethylated in only two of 10 (20%) MALM cases, but in 22 of 28 (78%) PALM + NALM cases ([Figure 3](#cancers-11-02031-f003){ref-type="fig"}).

Interestingly, methylation analysis of paired samples of primary tumor (PALM25) and metastatic tumor (MALM10) from the same patient demonstrated that their methylation profiles clustered with those of the corresponding primary and metastatic ALM groups, respectively ([Figure 2](#cancers-11-02031-f002){ref-type="fig"}C,D), revealing distinct methylation profiles.

Although the sample size was small, hypermethylation of IFITM1 was significantly more common in AMs lacking BRAF V600E mutations than in BRAF V600E--mutant AMs (*p* = 0.018).

2.7. Association of Aberrantly Methylated Genes in Metastatic AM with Clinicopathologic Parameters and Outcome {#sec2dot7-cancers-11-02031}
--------------------------------------------------------------------------------------------------------------

Hypermethylation of *IFITM1* and *SIK3* significantly correlated with worse DSS by univariate Cox proportional hazards regression analysis (*IFITM1*: HR, 3.88; 95% CI, 1.04 to 14.48; *p* = 0.044; *SIK3*: HR, 3.26; 95% CI, 1.02 to 10.39; *p* = 0.046) and Kaplan--Meier survival analysis ([Figure 1](#cancers-11-02031-f001){ref-type="fig"}G,H). Additionally, we noted a significant association of hypermethylation of cg09923443 (*SIK3*) and adverse histologic parameters in primary melanomas including ulceration and increased mitotic rate ([Table 2](#cancers-11-02031-t002){ref-type="table"}). This finding corroborated the potential impact of these two genes on primary tumor aggressiveness and early development of metastasis.

3. Discussion {#sec3-cancers-11-02031}
=============

Here, we demonstrate the epigenetic differences among melanomas occurring on acral sites but displaying different histopathological features. The four genes that were the most differentially methylated between PALM and NALM were *HHEX*, *NELFB/COBRA1*, *TEF*, and *DIPK2A/C3orf58*. Our findings suggest profound hypomethylation of the promoters of those genes in PALM compared to NALM. This finding is in line with the worse OS in patients who had hypermethylation of *HHEX* and *NELFB*.

*HHEX* (hematopoietically expressed homeobox) encodes a member of the homeobox family of transcription factors, many of which are involved in development, lymphangiogenesis, and hematopoietic stem cell differentiation \[[@B29-cancers-11-02031],[@B30-cancers-11-02031]\]. HHEX is a transcriptional regulator of the VEGFC/FLT4/PROX1 signaling axis involved in vascular development \[[@B29-cancers-11-02031]\]. HHEX was found to play a role in the migration and invasion of breast and prostate epithelial cells through the direct transcriptional regulation of *Endoglin*. The association of *HHEX* with hematopoietic, colorectal, liver, breast, prostate, and thyroid cancers has been extensively reported \[[@B31-cancers-11-02031],[@B32-cancers-11-02031],[@B33-cancers-11-02031],[@B34-cancers-11-02031],[@B35-cancers-11-02031],[@B36-cancers-11-02031],[@B37-cancers-11-02031],[@B38-cancers-11-02031]\].

*NELFB/COBRA1* (negative elongation factor/co-factor of BRCA1) encodes an essential component of the NELF complex, which negatively regulates the elongation of transcription by RNA polymerase II. The NELF complex acts in association with the DSIF \[5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) sensitivity-inducing factor\] complex, causing transcriptional pausing \[[@B39-cancers-11-02031]\]. Thus, hypermethylation of *NELFB*, which is believed to lead to global gene silencing, may result in cellular proliferation and promotion of tumorigenesis. This could explain, at least in part, the worse OS noted in the NALM group compared to the PALM group. *NELFB* appears to play an important role in other tumors including breast cancer, and its mRNA was found to be increased in breast cancer cell lines \[[@B40-cancers-11-02031]\]. An association of *NELFB* with prostate cancer and upper gastrointestinal adenocarcinomas, with overexpression of *NELFB* mRNA in these tumors, has been reported \[[@B39-cancers-11-02031],[@B41-cancers-11-02031]\].

*TEF* (transcriptional enhancer factor) encodes a member of the PAR (proline and acidic amino acid-rich) subfamily of bZIP (basic region/leucine zipper) transcription factors. The TEF/TEAD family of transcription factors are major mediators of YAP (Yes-associated protein) transcriptional activity. YAP and its paralog protein TAZ (transcriptional coactivator with PDZ-binding motif) are downstream effectors of the Hippo pathway and have been shown to facilitate the invasiveness and metastatic potential of melanoma cells \[[@B42-cancers-11-02031],[@B43-cancers-11-02031]\]. Recently, *YAP1* was found to be co-amplified with *PAK1* and *GAB2* on targeted genomic profiling of AM, which is in agreement with our finding of hypomethylation of the promoter of *TEF* \[[@B12-cancers-11-02031]\].

*DIPK2A* (divergent protein kinase domain 2A) encodes a protein-coding gene that plays a role in cardiomyocyte proliferation through paracrine signaling and activation of the PI3K-AKT-CDK7 signaling cascade \[[@B44-cancers-11-02031]\]. An association of *DIPK2A* with cancer has not been reported so far.

While PALM and NALM are epigenetically distinct, our data suggest that AMs, whether of PALM or NALM subtype, share a methylation signature and that the mechanism underlying metastasis is independent of the AM subtype (PALM or NALM). Among the top 50 DMPs, two probes, cg11694510 and cg09923443, localizing to the promoter regions of *IFITM1* and *SIK3*, respectively, showed profound hypomethylation in the primary tumors compared to the metastatic tumors, highlighting the role of these genes in early stromal invasion and initiation of metastasis.

*IFITM1* (interferon-induced transmembrane protein (1) is one of the interferon-stimulated genes that is STAT2 (signal transducer and activator of transcription (2) dependent, and its overexpression augments the proliferation, migration, and invasion of inflammatory breast cancer cells \[[@B45-cancers-11-02031]\]. *IFITM1* expression plays an important role in the invasion and progression of early-stage head and neck cancer and is overexpressed in these tumors \[[@B46-cancers-11-02031]\]; it also promotes metastasis of colorectal cancer \[[@B47-cancers-11-02031]\]. However, a role for *IFITM1* in melanoma has never been reported. Several studies have shown the therapeutic potential of *IFITM1* regulation in breast and cervical squamous cell carcinoma \[[@B48-cancers-11-02031],[@B49-cancers-11-02031]\]. This provides a rationale to investigate the therapeutic potential of agents targeting the regulation of this gene.

*SIK3* (salt-inducible kinase-3) encodes a salt-sensitive kinase that plays important roles in physiological functions including cell proliferation, apoptosis, and survival. *SIK3* expression is increased in the presence of salt and interleukin-17, leading to breast cancer cell proliferation. *SIK3* expression also increases the expression of chemokine CXCL12 and its specific receptor CXCR4 on cancer cells, promoting metastasis \[[@B50-cancers-11-02031]\]. *SIK3* is known to be associated with breast, hepatocellular, and ovarian cancer \[[@B51-cancers-11-02031]\]. It has also been reported to be involved in melanogenesis through the cAMP-response element binding protein and its activator LKB1 (liver kinase B1) \[[@B52-cancers-11-02031]\]. *STK11* (also known as *LKB1* and *PAR-4*) encodes a serine/threonine kinase found in approximately 10% of melanomas \[[@B53-cancers-11-02031]\]. Interestingly, when all AM cases (PALM, NALM, and MALM) were analyzed together, hypermethylation of *IFITM1* and *SIK3* was associated with worse OS. This finding corroborated the potential role of these genes in early stromal invasion and initiation of metastasis.

In agreement with previous studies on CM, we identified significant associations between aberrant methylation and aggressive clinicopathologic parameters in AM including the presence of lymph node metastasis, ulceration, increased mitoses, and higher Breslow thickness \[[@B21-cancers-11-02031],[@B22-cancers-11-02031],[@B23-cancers-11-02031],[@B24-cancers-11-02031],[@B25-cancers-11-02031],[@B26-cancers-11-02031]\]. In addition, our study revealed significant correlation between aberrant methylation of *HHEX*, *DIPK2A*, *NELFB/COBRA1*, *CDH13*, *TEF*, *IFITM1*, and *SIK3* and worse DSS.

A recent study interrogating AMs by targeted deep sequencing identified two distinct subtypes of melanoma on acral sites: the *BRAF* mutant, similar to nonacral melanoma, and non-*BRAF* mutant \[[@B12-cancers-11-02031]\]. Interestingly, in our small cohort, we observed that the hypermethylation of IFITM1 was significantly more common in *BRAF* V600E negative AMs than in *BRAF* V600E-mutant AMs. Although validation by larger studies is warranted, it could be hypothesized that these distinct genetic subtypes of AMs harbor distinct methylation profiles.

There are some limitations in our study:(1) Relatively small sample size; (2) retrospective study; (3) in our cases, conventional prognostic indicators did not reveal statistical significance; (4) treatment regimens and surgical management have not been considered in survival analysis; and (5) we did not confirm the differential expression of methylated (hypo- versus hyper-) genes in AMs, although the project is under consideration.

Regardless, the epigenetic biomarkers identified in our study serve as a rationale to further validate these findings on larger independent cohorts. Once validated, these findings would serve to risk-stratify AM patients at their early disease stage (primary tumors) for more aggressive adjuvant treatment regimens. They may serve as potential therapeutic targets with methylation modulators for personalized management of patients with these tumors.

4. Materials and Methods {#sec4-cancers-11-02031}
========================

4.1. Patient Cohort {#sec4dot1-cancers-11-02031}
-------------------

After receiving institutional review board approval (PA12-0494), we reviewed our pathology database and identified all cases of PALM, NALM, MALM, PCM, and AN diagnosed at our institution during 2002--2018. We excluded cases for which either tissue was not available in our institutional repository or the amount of DNA extracted from the tumor was not sufficient for methylation studies, generating the following final cohort for our study: 22 PALM, nine NALM, 10 MALM, nine PCM, and three AN. All slides for each case were reviewed by two pathologists (DP and PPA) to confirm the diagnosis and select the most viable tumor areas for DNA extraction. The clinicopathologic features of one case of NALM were not available, and this case was excluded from the analyses of survival and histologic parameters. We also had paired samples of MALM and PALM from one patient, and only the PALM sample was included in the survival and histologic analyses.

4.2. DNA Isolation, Methylation Analysis, Functional Genomic Pathway Analysis, and Statistical Analysis {#sec4dot2-cancers-11-02031}
-------------------------------------------------------------------------------------------------------

DNA isolation, methylation analysis, and functional genomic pathway analysis were performed as described in our previous publication \[[@B54-cancers-11-02031]\] (please see details in the [Supplementary Methods in Supplementary Materials](#app1-cancers-11-02031){ref-type="app"}, available online). Briefly, DNA extraction (Thermo Fisher) followed by bisulfite conversion (Zymo Research, Irvine, CA, USA) was performed as per the manufacturer's instructions. The Infinium Methylation EPIC array (Illumina, San Diego, CA, USA) was used to determine the DNA methylation status of 866,562 CpG sites, following the manufacturer's instructions. The DMPs finder function in minfi was used to identify DMPs for three different comparisons: (1) PALM versus NALM, (2) PALM versus MALM (3), and AM (PALM + NALM) versus MALM. Three PALMs and four PCMs did not pass the quality-control test for the assay and hence were excluded from the analysis. All statistical analyses were performed using SAS 9.4 for Windows (SAS Institute Inc., Cary, NC, USA).

4.3. Data Access {#sec4dot3-cancers-11-02031}
----------------

IDAT files of our cohort (48 samples) have been deposited in Gene Expression Omnibus, accession number GSE133395. The R script used for the analysis has been uploaded to Github (<https://github.com/varshivasu7/minfi_Illumina_methylation>) \[[@B54-cancers-11-02031]\].

5. Conclusions {#sec5-cancers-11-02031}
==============

In conclusion, we have identified four novel epigenetic prognostic biomarkers in AM: *HHEX*, *NELFB*, *IFITM1*, and *SIK3*. Hypermethylation in the promoter region of these genes is significantly associated with aggressive clinicopathologic parameters including greater Breslow thickness, ulceration, increased mitotic rate, and lymph node metastasis and worse DSS in AM. Our study also revealed that PALM and NALM are epigenetically distinct subtypes and that NALM is associated with worse DSS; this emphasizes the importance of distinguishing these two types. These are promising findings that, after further validation through larger studies and mechanistic functional studies, can be translated in the clinical setting. Once validated, the epigenetic biomarkers identified in this study can serve to stratify patients for more aggressive treatment regimens. Our study confirms methylation array testing as a robust approach for epigenetic analysis that is resistant to factors that are known to interfere with gene expression analysis including formalin fixation, ischemia time, and others. Finally, our study provides a rationale to investigate agents targeting epigenetic regulation in AM, potentially expanding the limited therapeutic options currently available to patients with this disease.
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![Results of methylation analyses. (**A**,**C**,**E**,**G**): Unsupervised hierarchical clustering heatmaps with different β-scores for the 50 most significantly differentially methylated gene-coding and non-gene-coding CpG islands (i.e., lowest *p* and *q* values \[*p* \< 0.05; *q* \< 0.01\]). The heatmap shows distinct methylation profiles between (**A**) PALM and NALM, (**C**) PALM and MALM, (**E**) PALM + NALM and MALM and (**G**) NALM and MALM. Loci hypermethylated in one tumor are hypomethylated in the other and vice versa. (In the heatmap: RED corresponds to hypermethylation or low gene expression and BLUE corresponds to hypomethylation or high gene expression) (**B**,**D**,**F**,**H**): Three-dimensional T-distributed stochastic neighbor embedding (t-SNE) showing the distribution of cases classified on the basis of differentially methylated probes adjusted for age and sex. The algorithm calculates the similarity of the patient samples in the two compared groups in a 3-dimensional space, in this case labeled as t-SNE1; t-SNE2; and t-SNE3. The numbers in the three different axes do not have units; they represent the approximate distance between the two different groups/clusters and reflect whether they are truly distinct or not. (**B**) NALM (red dots) and PALM (green dots) show no neighboring and discrete clusters. (**D**) MALM (red dots) and PALM (green dots) showing discrete clusters. Note that case MALM 5 (circle) is an outlier that clusters with the PALM group. The blue arrows indicate paired samples from the same patient. (**F**) MALM (red dots) and PALM + NALM (green dots). Note that case MALM5 (circle) is an outlier that clusters with the PALM + NALM group. (**H**) NALM (green dots) and MALM (red dots) show discrete clusters with the exception of MALM5 (circle) that clusters with the NALM group.](cancers-11-02031-g002){#cancers-11-02031-f002}

![Prevalence and degree of hypomethylation (using the raw β score) of the probes of interest across the studied samples. (**A**) Significant probes associated with PALM vs. NALM: cg26732804 (*HHEX*), cg07088959 (*DIPK2A*), cg21298070 (*TEF*), and cg14397361 (*NELFB).* (**B**) Significant probes associated with metastasis of AM: cg11694510 (*IFITM1)* and cg09923443 (*SIK3)*. (**C**) Significant probes associated with metastasis of AM: cg24666276 (*MYC)*. In each panel, each column represents one sample; the top row indicates the clinical outcome of the patient that the sample came from; and each row indicates the degree of hypomethylation of the corresponding probe/gene in that sample.](cancers-11-02031-g003){#cancers-11-02031-f003}
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###### 

Summary of patient and clinical characteristics overall and by melanoma subtype \*.

  Characteristic                                                      All (N = 48)        PALM (N = 22)        MALM (N = 9) ^†^      NALM (N = 8) ^†^       PCM (N = 9)          *p* Value \#
  ------------------------------------------------------------------- ------------------- -------------------- --------------------- ---------------------- -------------------- --------------
  Sex                                                                                                                                                                            
  Male                                                                30 (63)             14 (64)              5 (56)                5 (63)                 6 (67)               0.97
  Female                                                              18 (38)             8 (36)               4 (44)                3 (38)                 3 (33)               
  Age, median (range), y                                              62.1 (1.7--90.6)    67.4 (36.6--90.6)    58.4 (16.0--79.0)     55.6 (1.7--89.4)       62.3 (13.7--79.0)    0.22
  Race                                                                                                                                                                           
  White                                                               40 (83)             16 (73)              8 (89)                7 (88)                 9 (100)              0.34
  Other                                                               8 (17)              6 (27)               1 (11)                1 (13)                 0                    
  AJCC 8th edition stage at presentation                                                                                                                                         
  I                                                                   10 (21)             6 (27)               1 (13)                1 (13)                 2 (22)               0.37
  II                                                                  15 (32)             7 (32)               1 (13)                2 (25)                 5 (56)               
  III                                                                 21 (45)             9 (41)               6 (75)                4 (50)                 2 (22)               
  IV                                                                  1 (2)               0                    0                     1 (13)                 0                    
  Site(s) of LN metastasis at diagnosis                                                                                                                                          
  None                                                                25 (54)             13 (59)              3 (33)                1 (17)                 8 (89)               **0.019**
  Enlarged ^‡^                                                        1 (2)               1 (5)                0                     0                      0                    
  Regional                                                            1 (2)               0                    1 (11)                0                      0                    
  Sentinel                                                            17 (37)             8 (36)               3 (33)                5 (83)                 1 (11)               
  Regional and sentinel                                               2 (4)               0                    2 (22)                0                      0                    
  Total number of LNs with metastasis at diagnosis, median (range)    2 (1--11)           2 (1--3)             4 (1--11)             2 (1--2)               1 (1--1)             0.24
  Primary histologic subtype                                                                                                                                                     
  ALM                                                                 31 (65)             22 (100)             9 (100)               0                      0                    **\<0.001**
  LMM                                                                 2 (4)               0                    0                     0                      2 (22)               
  NM                                                                  6 (13)              0                    0                     4 (50)                 2 (22)               
  SSM                                                                 5 (10)              0                    0                     3 (38)                 2 (22)               
  Unclassified                                                        4 (8)               0                    0                     1 (13)                 3 (33)               
  Clark level                                                                                                                                                                    
  II                                                                  1 (2)               1 (5)                0                     0                      0                    0.79
  III                                                                 1 (2)               0                    0                     1 (13)                 0                    
  IV                                                                  32 (68)             15 (68)              6 (75)                4 (50)                 7 (78)               
  V                                                                   13 (27)             6 (27)               2 (22)                3 (38)                 2 (22)               
  Breslow thickness, mm                                                                                                                                                          
  1.01--2                                                             13 (28)             7 (33)               2 (25)                2 (25)                 2 (22)               0.34
  2.01--4                                                             14 (30)             4 (19)               1 (13)                4 (50)                 5 (56)               
  \>4                                                                 19 (41)             10 (48)              5 (63)                2 (25)                 2 (22)               
  Radial growth phase                                                                                                                                                            
  Present                                                             25 (74)             13 (87)              6 (100)               2 (33)                 4 (57)               **0.021**
  Not identified                                                      9 (26)              2 (13)               0                     4 (67)                 3 (43)               
  Vertical growth phase                                                                                                                                                          
  Present                                                             46 (100)            22 (100)             8 (100)               7 (100)                9 (100)              
  Not identified                                                      0                   0                    0                     0                      0                    
  Mitotic figures                                                                                                                                                                
  \<1                                                                 2 (5)               1 (5)                0                     1 (17)                 0                    0.49
  1--4                                                                30 (68)             14 (64)              5 (63)                3 (50)                 8 (100)              
  5--9                                                                5 (11)              3 (14)               2 (25)                0                      0                    
  10--20                                                              5 (11)              2 (9)                1 (13)                2 (33)                 0                    
  \>20                                                                2 (5)               2 (9)                0                     0                      0                    
  Ulceration                                                                                                                                                                     
  Present                                                             21 (48)             11 (52)              6 (75)                2 (29)                 2 (25)               0.18
  Not identified                                                      23 (52)             10 (48)              2 (25)                5 (71)                 6 (75)               
  Regression                                                                                                                                                                     
  Present                                                             6 (14)              4 (18)               1 (13)                0                      1 (13)               0.92
  Not identified                                                      38 (86)             18 (82)              7 (88)                6 (100)                7 (88)               
  Vascular invasion                                                                                                                                                              
  Present                                                             6 (13)              2 (9)                1 (11)                3 (50)                 0                    **0.05**
  Not identified                                                      40 (87)             20 (91)              8 (89)                3 (50)                 9 (100)              
  Perineural invasion                                                                                                                                                            
  Present                                                             13 (30)             7 (32)               3 (38)                2 (33)                 1 (13)               0.73
  Not identified                                                      31 (70)             15 (68)              5 (63)                4 (67)                 7 (88)               
  Microscopic satellitosis                                                                                                                                                       
  Present                                                             4 (9)               2 (9)                0                     1 (17)                 1 (13)               0.71
  Not identified                                                      40 (91)             20 (91)              8 (100)               5 (83)                 7 (88)               
  TIL                                                                                                                                                                            
  Non-brisk                                                           45 (100)            22 (100)             8 (100)               7 (100)                8 (100)              
  Brisk                                                               0                   0                    0                     0                      0                    
  Associated nevus                                                                                                                                                               
  Present                                                             3 (7)               1 (5)                0                     0                      2 (25)               0.23
  Not identified                                                      41 (93)             21 (95)              8 (100)               6 (100)                6 (75)               
  Predominant cytology                                                                                                                                                           
  Epithelioid                                                         28 (64)             14 (67)              4 (50)                6 (86)                 4 (50)               0.22
  Nevoid                                                              5 (11)              2 (10)               0                     0                      3 (38)               
  Spindled                                                            11 (25)             5 (24)               4 (50)                1 (14)                 1 (13)               
  Genetic mutation                                                                                                                                                               
  Yes                                                                 15 (48)             6 (38)               4 (44)                3 (100)                2 (67)               0.29
  No                                                                  16 (52)             10 (63)              5 (56)                0                      1 (33)               
  Vital status                                                                                                                                                                   
  Alive with NED                                                      20 (42)             12 (55)              1 (11)                2 (25)                 5 (56)               **0.006**
  Alive with disease                                                  7 (15)              5 (23)               2 (22)                0                      0                    
  Died of other causes                                                8 (17)              3 (14)               0                     2 (25)                 3 (33)               
  Died with disease                                                   13 (27)             2 (9)                6 (67)                4 (50)                 1 (11)               
  Follow-up time after diagnosis (all patients), median (range), mo   54.9 (5.2--186.0)   47.7 (11.0--186.0)   72.1 (25.0--141.1)    43.0 (7.1--147.8)      93.7 (5.2--123.9)    0.42
  Survival time after diagnosis (survivors) ^§^, months                                                                                                                          
  Number of patients                                                  27                  17                   3                     2                      5                    0.07
  Median (range)                                                      68.0 (5.2--186.0)   48.9 (18.6--186.0)   103.8 (29.7--141.1)   136.5 (125.1--147.8)   93.7 (57.6--123.9)   

Abbreviations: LMM, lentigo maligna melanoma; MALM, metastatic ALM; NALM, primary non-lentiginous AM involving acral sites; LN, lymph node; NED, no evidence of diseases; NM, nodular melanoma; PALM, primary acral lentiginous melanoma; PCM, primary non-acral cutaneous melanoma; SSM, superficial spreading melanoma; TIL, tumor-infiltrating lymphocytes. \* Values in table are number of patients (percentage) unless otherwise indicated. ^†^ The clinicopathologic features of 1 case of NALM were not available, hence clinicopathologic data of 8 NALM cases are provided in this table although methylation of 9 NALM cases was analyzed. Also, we had paired samples of MALM and PALM from the same patient in one case, and only the PALM data were used in the survival and histologic analyses. ^‡^ Enlarged means that the patient had enlarged nodes clinically but nodal metastasis was not confirmed histopathologically. ^§^ For the patients still alive at their last follow-up visit. \# Statistically significant *p* values (≤ 0.05) are marked in bold.
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###### 

Associations between survival and histologic parameters and β-score optimal cutoff groups (univariate analysis) \*.

  ------------------------------------------------- ----------- ----------------------- ---------------
  **Survival**                                      **Genes**   **HR (95% CI)**         ***p* Value**
  Overall                                           *CDH13*     0.29 (0.10 to 0.84)     0.022
                                                    *NELFB*     4.75 (1.61 to 13.99)    0.005
                                                    *HHEX*      4.60 (1.63 to 13.00)    0.004
  Disease-specific                                  *CDH13*     0.22 (0.06 to 0.74)     0.014
                                                    *DIPK2A*    5.09 (1.11 to 23.34)    0.036
                                                    *NELFB*     7.17 (1.92 to 26.76)    0.003
                                                    *TEF*       4.59 (1.21 to 17.43)    0.025
                                                    *HHEX*      6.13 (1.83 to 20.49)    0.003
                                                    *SIK3*      3.26 (1.02 to 10.39)    0.046
                                                    *IFITM1*    3.88 (1.04 to 14.48)    0.044
  **Histologic Parameter**                          **Genes**   **HR (95% CI)**         ***p*-value**
  Lymph node metastasis at diagnosis (yes vs. no)   *CDH13*     0.14 (0.02 to 0.77)     0.025
                                                    *NELFB*     5.50 (1.16 to 26.14)    0.032
                                                    *HHEX*      7.50 (1.61 to 34.95)    0.010
  Predominant histologic subtype (ALM vs. other)    *DIPK2A*    0.04 (0.00 to 0.38)     0.005
                                                    *NELFB*     0.04 (0.00 to 0.93)     0.044
                                                    *TEF*       0.06 (0.01 to 0.38)     0.003
                                                    *HHEX*      0.06 (0.01 to 0.38)     0.003
                                                    *IFITM1*    10.82 (1.17 to 100.4)   0.036
  Breslow thickness (\>4 mm vs. 1.01--4 mm)         *CDH13*     0.12 (0.02 to 0.59)     0.009
  Mitotic figures (≥10 vs. \<4)                     *CDH13*     0.19 (0.04 to 0.92)     0.040
                                                    *TEF*       14.44 (1.56 to 133.6)   0.019
                                                    *SIK3*      9.07 (1.72 to 47.67)    0.009
  Ulceration (present vs. not identified)           *CDH13*     0.06 (0.01 to 0.56)     0.013
                                                    *SIK3*      7.94 (1.60 to 39.42)    0.011
  PNI (present vs. not identified)                  *CDH13*     0.07 (0.01 to 0.64)     0.019
  ------------------------------------------------- ----------- ----------------------- ---------------

Abbreviations: CI, confidence interval; HR, hazard ratio; PNI, perineural invasion. \* β score comparisons were hypermethylated versus hypomethylated.

[^1]: These authors have contributed equally to this study.
